Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

References

• Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther. 2014;10:469–478.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–691.
   PubMed Web of Science ®Google Scholar
• Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384–400.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30–39.
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277(1):8–21.
   PubMed Web of Science ®Google Scholar
• Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017–present). Expert Opin Ther Pat. 2020;30(4):263–274.
   PubMed Web of Science ®Google Scholar
• Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11):591–601.
   PubMed Web of Science ®Google Scholar
• Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J. 2016;52(1):1–11.
   PubMedGoogle Scholar
• Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int. 2016;2016:8797206.
   PubMed Web of Science ®Google Scholar
• Hai Y, Christianson DW. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat Chem Biol. 2016;12(9):741–747.
   PubMed Web of Science ®Google Scholar
• Li G, Jiang H, Chang M, Xie H, Hu L. HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. J Neurol Sci. 2011;304(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601–607.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, Zhang W, Yang J. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11(1):111.
   PubMed Web of Science ®Google Scholar
• Shen S, Kozikowski AP. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019). Expert Opin Ther Pat. 2020;30(2):121–136.
   PubMed Web of Science ®Google Scholar
• Zhong F, Cheng X, Sun S, Zhou J. Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. Oncol Rep. 2017;37(5):3061–3067.
   PubMed Web of Science ®Google Scholar
• Dhanak D, Edwards JP, Nguyen A, Tummino PJ. Small-molecule targets in immuno-oncology. Cell Chem Biol. 2017;24(9):1148–1160.
   PubMed Web of Science ®Google Scholar
• Rebe C, Ghiringhelli F. STAT3, a master regulator of anti-tumor immune response. Cancers. 2019;11(9):1280.
   PubMed Web of Science ®Google Scholar
• Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol. 2014;193(6):2850–2862.
   PubMed Web of Science ®Google Scholar
• Noonepalle S, Shen S, Ptacek J, Tavares MT, Zhang G, Stransky J, Pavlicek J, Ferreira GM, Hadley M, Pelaez G, et al. Rational design of suprastat: a novel selective histone deacetylase 6 inhibitor with the ability to potentiate immunotherapy in melanoma models. J Med Chem. 2020;63(18):10246–10262.
   PubMed Web of Science ®Google Scholar
• Peng X, Li L, Chen J, Ren Y, Liu J, Yu Z, Cao H, Chen J. Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma. J Med Chem. 2022;65(3):2434–2457.
   PubMed Web of Science ®Google Scholar
• Peng X, Chen J, Li L, Sun Z, Liu J, Ren Y, Huang J, Chen J. Efficient synthesis and bioevaluation of novel dual tubulin/histone deacetylase 3 inhibitors as potential anticancer agents. J Med Chem. 2021;64(12):8447–8473.
   PubMed Web of Science ®Google Scholar
• Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 2010;132(31):10842–10846.
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003;63(13):3637–3645.
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22(5):1026–1034.
   PubMed Web of Science ®Google Scholar
• Geraldy M, Morgen M, Sehr P, Steimbach RR, Moi D, Ridinger J, Oehme I, Witt O, Malz M, Nogueira MS, et al. Selective inhibition of histone deacetylase 10: hydrogen bonding to the gatekeeper residue is implicated. J Med Chem. 2019;62(9):4426–4443.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Qin M, Wu HP, Khamis MY, Li YH, Ma LY, Liu HM. A review of progress in histone deacetylase 6 inhibitors research: structural specificity and functional diversity. J Med Chem. 2021;64(3):1362–1391.
   PubMed Web of Science ®Google Scholar
• Ray A, Das DS, Song Y, Hideshima T, Tai YT, Chauhan D, Anderson KC. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2018;32(3):843–846.
   PubMed Web of Science ®Google Scholar
• Gaisina IN, Tueckmantel W, Ugolkov A, Shen S, Hoffen J, Dubrovskyi O, Mazar A, Schoon RA, Billadeau D, Kozikowski AP. Identification of HDAC6-selective inhibitors of low cancer cell cytotoxicity. ChemMedChem. 2016;11(1):81–92.
   PubMed Web of Science ®Google Scholar
• Auzmendi-Iriarte J, Saenz-Antonanzas A, Mikelez-Alonso I, Carrasco-Garcia E, Tellaetxe-Abete M, Lawrie CH, Sampron N, Cortajarena AL, Matheu A. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis. 2020;11(6):417.
   PubMed Web of Science ®Google Scholar
• Vergani B, Sandrone G, Marchini M, Ripamonti C, Cellupica E, Galbiati E, Caprini G, Pavich G, Porro G, Rocchio I, et al. Novel benzohydroxamate-based potent and selective histone deacetylase 6 (HDAC6) inhibitors bearing a pentaheterocyclic scaffold: design, synthesis, and biological evaluation. J Med Chem. 2019;62(23):10711–10739.
   PubMed Web of Science ®Google Scholar
• Porter NJ, Osko JD, Diedrich D, Kurz T, Hooker JM, Hansen FK, Christianson DW. Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity. J Med Chem. 2018;61(17):8054–8060.
   PubMed Web of Science ®Google Scholar
• Osko JD, Porter NJ, Narayana Reddy PA, Xiao YC, Rokka J, Jung M, Hooker JM, Salvino JM, Christianson DW. Exploring structural determinants of inhibitor affinity and selectivity in complexes with histone deacetylase 6. J Med Chem. 2020;63(1):295–308.
   PubMed Web of Science ®Google Scholar
• Campiani G, Cavella C, Osko JD, Brindisi M, Relitti N, Brogi S, Saraswati AP, Federico S, Chemi G, Maramai S, et al. Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors. J Med Chem. 2021;64(14):9960–9988.
   PubMed Web of Science ®Google Scholar
• Wu YW, Hsu KC, Lee HY, Huang TC, Lin TE, Chen YL, Sung TY, Liou JP, Hwang-Verslues WW, Pan SL, et al. A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo. Front Pharmacol. 2018;9:205.
   PubMed Web of Science ®Google Scholar
• Nepali K, Chang TY, Lai MJ, Hsu KC, Yen Y, Lin TE, Lee SB, Liou JP. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. Eur J Med Chem. 2020;196:112291.
   PubMed Web of Science ®Google Scholar
• Lee HY, Nepali K, Huang FI, Chang CY, Lai MJ, Li YH, Huang HL, Yang CR, Liou JP. (N-Hydroxycarbonylbenzylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo. J Med Chem. 2018;61(3):905–917.
   PubMed Web of Science ®Google Scholar
• Lee HY, Fan SJ, Huang FI, Chao HY, Hsu KC, Lin TE, Yeh TK, Lai MJ, Li YH, Huang HL, et al. 5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer’s disease phenotypes. J Med Chem. 2018;61(16):7087–7102.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li X, Chen Y, Wan M, Jiang Q, Zhang L, Chou CJ, Song W, Zhang L. Discovery of N-(2-aminophenyl)-4-(bis(2-chloroethyl)amino)benzamide as a potent histone deacetylase inhibitor. Front Pharmacol. 2019;10:957.
   PubMed Web of Science ®Google Scholar
• Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, et al. Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents. J Med Chem. 2020;63(15):8338–8358.
   PubMed Web of Science ®Google Scholar
• Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004;64(7):2590–2600.
   PubMed Web of Science ®Google Scholar
• Gunaydin C, Celik ZB, Bilge SS, Avci B, Kara N. SAHA attenuates rotenone-induced toxicity in primary microglia and HT-22 cells. Toxicol Ind Health. 2021;37(1):23–33.
   PubMed Web of Science ®Google Scholar